Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study-Reference-Cited by-同舟云学术

Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study

Published:2017-09 Issue:1 Volume:5 Page:e000424
ISSN:2052-4897
Container-title:BMJ Open Diabetes Research & Care
language:en
Short-container-title:BMJ Open Diab Res Care

Author:

Inagaki Nobuya,Chou Hubert S,Tsukiyama Shuji,Washio Takuo,Shiosakai Kazuhito,Nakatsuka Yasuhiko,Taguchi Takashi

Funder

Daiichi-Sankyo Co., Ltd.

Publisher

BMJ

Subject

Endocrinology, Diabetes and Metabolism

Reference25 articles.

1. Evidence-based practice guideline for the treatment for diabetes in Japan 2013;Tajima;Diabetol Int,2015

2. Standards of medical care in diabetes;American Diabetes Association;Diabetes Care,2016

3. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release;Chu;Endocrinology,2008

4. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release;Chu;Endocrinology,2007

5. Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag;Chepurny;Mol Endocrinol,2013

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates;Expert Opinion on Investigational Drugs;2024-02-23

2. GPCRs involved in metabolic diseases: pharmacotherapeutic development updates;Acta Pharmacologica Sinica;2024-02-07

3. Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolabeled compounds and in vitro studies;Drug Metabolism and Pharmacokinetics;2022-08

4. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus;Bioorganic Chemistry;2021-08

5. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease;Cellular & Molecular Biology Letters;2021-07-07